Search

Your search keyword '"Follows, George"' showing total 573 results
Start Over Author "Follows, George"
573 results on '"Follows, George"'

1. Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial

Author

Niemann, Carsten U, Munir, Talha, Moreno, Carol, Owen, Carolyn, Follows, George A, Benjamini, Ohad, Janssens, Ann, Levin, Mark-David, Robak, Tadeusz, Simkovic, Martin, Voloshin, Sergey, Vorobyev, Vladimir, Yagci, Munci, Ysebaert, Loic, Qi, Keqin, Qi, Qianya, Sinet, Pierre, Parisi, Lori, Srinivasan, Srimathi, Schuier, Natasha, Baeten, Kurt, Howes, Angela, Caces, Donne Bennett, and Kater, Arnon P

Published
2023
Full Text
View/download PDF

3. Procarbazine-induced Genomic Toxicity in Hodgkin Lymphoma Survivors

Author

Santarsieri, Anna, primary, Mitchell, Emily, additional, Pham, My H., additional, Sanghvi, Rashesh, additional, Jablonski, Janina, additional, Lee-Six, Henry, additional, Sturgess, Katherine, additional, Brice, Pauline, additional, Menne, Tobias F., additional, Osborne, Wendy, additional, Creasey, Thomas, additional, Ardeshna, Kirit M., additional, Baxter, Joanna, additional, Behan, Sarah, additional, Bhuller, Kaljit, additional, Booth, Stephen, additional, Chavda, Nikesh D., additional, Collins, Graham P., additional, Culligan, Dominic J., additional, Cwynarski, Kate, additional, Davies, Andrew, additional, Downing, Abigail, additional, Dutton, David, additional, Furtado, Michelle, additional, Gallop-Evans, Eve, additional, Hodson, Andrew, additional, Hopkins, David, additional, Hsu, Hannah, additional, Iyengar, Sunil, additional, Jones, Stephen G., additional, Karanth, Mamatha, additional, Linton, Kim M., additional, Lomas, Oliver C., additional, Martinez-Calle, Nicolas, additional, Mathur, Abhinav, additional, McKay, Pamela, additional, Nagumantry, Sateesh K., additional, Phillips, Elizabeth H., additional, Phillips, Neil, additional, Rudge, John F., additional, Shah, Nimish K., additional, Stafford, Gwyneth, additional, Sternberg, Alex, additional, Trickey, Rachel, additional, Uttenthal, Benjamin J., additional, Wetherall, Natasha, additional, Zhang, Xiao-Yin, additional, McMillan, Andrew K., additional, Coleman, Nicholas, additional, Stratton, Michael R., additional, Laurenti, Elisa, additional, Borchmann, Peter, additional, Borchmann, Sven, additional, Campbell, Peter J., additional, Rahbari, Raheleh, additional, and Follows, George A., additional

Published
2024
Full Text
View/download PDF

4. Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study

Author

Schuster, Michael, Zijlstra, Josée, Casasnovas, Rene-Olivier, Vermaat, Joost S.P, Kalakonda, Nagesh, Goy, Andre, Choquet, Sylvain, Neste, Eric Van Den, Hill, Brian, Thieblemont, Catherine, Cavallo, Federica, De la Cruz, Fatima, Kuruvilla, John, Hamad, Nada, Jaeger, Ulrich, Caimi, Paolo, Gurion, Ronit, Warzocha, Krzysztof, Bakhshi, Sameer, Sancho, Juan-Manuel, Follows, George, Egyed, Miklos, Offner, Fritz, Vassilakopoulos, Theodoros, Samal, Priyanka, Ku, Matthew, Ma, Xiwen, Corona, Kelly, Chamoun, Kamal, Shah, Jatin, Shacham, Sharon, Kauffman, Michael G., Canales, Miguel, and Maerevoet, Marie

Published
2022
Full Text
View/download PDF

5. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia

Author

Sharman, Jeff P., Egyed, Miklos, Jurczak, Wojciech, Skarbnik, Alan, Pagel, John M., Flinn, Ian W., Kamdar, Manali, Munir, Talha, Walewska, Renata, Corbett, Gillian, Fogliatto, Laura Maria, Herishanu, Yair, Banerji, Versha, Coutre, Steven, Follows, George, Walker, Patricia, Karlsson, Karin, Ghia, Paolo, Janssens, Ann, Cymbalista, Florence, Woyach, Jennifer A., Ferrant, Emmanuelle, Wierda, William G., Munugalavadla, Veerendra, Yu, Ting, Wang, Min Hui, and Byrd, John C.

Published
2022
Full Text
View/download PDF

6. Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes

Author

Casasnovas, Rene-Olivier, Follows, George, Zijlstra, Josee M., Vermaat, Joost S.P., Kalakonda, Nagesh, Choquet, Sylvain, Neste, Eric Van Den, Hill, Brian, Thieblemont, Catherine, Cavallo, Federica, la Cruz, Fatima De, Kuruvilla, John, Hamad, Nada, Jaeger, Ulrich, Caimi, Paolo F., Gurion, Ronit, Warzocha, Krzysztof, Bakhshi, Sameer, Sancho, Juan-Manuel, Schuster, Michael, Egyed, Miklos, Offner, Fritz, Vassilakopoulos, Theodoros P., Samal, Priyanka, Ku, Matthew, Ma, Xiwen, Chamoun, Kamal, Shah, Jatin, Canales, Miguel, Maerevoet, Marie, Shacham, Sharon, Kauffman, Michael G., and Goy, Andre

Published
2022
Full Text
View/download PDF

8. The long-term effects of chemotherapy on normal blood cells

Author

Mitchell, Emily, primary, Pham, My H., additional, Clay, Anna, additional, Sanghvi, Rashesh, additional, Pietsch, Sandra, additional, Hsu, Joanne I., additional, Jung, Hyunchul, additional, Vedi, Aditi, additional, Moody, Sarah, additional, Wang, Jingwei, additional, Leonganmornlert, Daniel, additional, Chapman, Michael Spencer, additional, Williams, Nicholas, additional, Dunstone, Ellie, additional, Santarsieri, Anna, additional, Cagan, Alex, additional, Machado, Heather E., additional, Baxter, Joanna, additional, Follows, George, additional, Hodson, Daniel J, additional, McDermott, Ultan, additional, Doherty, Gary J., additional, Martincorena, Inigo, additional, Humphreys, Laura, additional, Mahbubani, Krishnaa, additional, Parsy, Kourosh Saeb, additional, Takahashi, Koichi, additional, Goodell, Margaret A., additional, Kent, David, additional, Laurenti, Elisa, additional, Campbell, Peter J., additional, Rahbari, Raheleh, additional, Nangalia, Jyoti, additional, and Stratton, Michael R., additional

Published
2024
Full Text
View/download PDF

11. Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial

Author

Russell, James, Collins, Angela, Fowler, Alexis, Karanth, Mamatha, Saha, Chandan, Docherty, Suzanne, Padayatty, Joseph, Maw, Kyaw, Lentell, Isabel, Cooke, Lisa, Hodson, Andrew, Shah, Nimish, Sadullah, Shalal, Grigoropoulos, Nicholas, Qian, Wendi, Kirkwood, Amy A., Uttenthal, Benjamin J., Johnson, Peter, and Follows, George A.

Published
2021
Full Text
View/download PDF

12. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial

Author

Kalakonda, Nagesh, Maerevoet, Marie, Cavallo, Federica, Follows, George, Goy, Andre, Vermaat, Joost S P, Casasnovas, Olivier, Hamad, Nada, Zijlstra, Josée M, Bakhshi, Sameer, Bouabdallah, Reda, Choquet, Sylvain, Gurion, Ronit, Hill, Brian, Jaeger, Ulrich, Sancho, Juan Manuel, Schuster, Michael, Thieblemont, Catherine, De la Cruz, Fátima, Egyed, Miklos, Mishra, Sourav, Offner, Fritz, Vassilakopoulos, Theodoros P, Warzocha, Krzysztof, McCarthy, Daniel, Ma, Xiwen, Corona, Kelly, Saint-Martin, Jean-Richard, Chang, Hua, Landesman, Yosef, Joshi, Anita, Wang, Hongwei, Shah, Jatin, Shacham, Sharon, Kauffman, Michael, Van Den Neste, Eric, and Canales, Miguel A

Published
2020
Full Text
View/download PDF

13. Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study

Author

Maerevoet, Marie, Zijlstra, Josee M., Follows, George, Casasnovas, Rene-Olivier, Vermaat, J. S. P., Kalakonda, Nagesh, Goy, Andre, Choquet, Sylvain, Van Den Neste, Eric, Hill, Brian, Thieblemont, Catherine, Cavallo, Federica, De la Cruz, Fatima, Kuruvilla, John, Hamad, Nada, Jaeger, Ulrich, Caimi, Paolo, Gurion, Ronit, Warzocha, Krzysztof, Bakhshi, Sameer, Sancho, Juan-Manuel, Schuster, Michael, Egyed, Miklos, Offner, Fritz, Vassilakopoulos, Theodoros P., Samal, Priyanka, Ku, Matthew, Ma, Xiwen, Corona, Kelly, Chamoun, Kamal, Shah, Jatin, Shacham, Sharon, Kauffman, Michael G., and Canales, Miguel

Published
2021
Full Text
View/download PDF

14. DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes

Author

Kizhakeyil, Atish, Zaini, Nurmahirah Binte Mohammed, Poh, Zhi Sheng, Wong, Brandon Han Siang, Loh, Xinpeng, Ng, Aik Seng, Low, Zun Siong, Prasannan, Praseetha, Gong, Chun, Tan, Michelle Guet Khim, Nagarajan, Chandramouli, Huang, Dachuan, Lu, Pang Wan, Lim, Jing Quan, Barrans, Sharon, Ong, Choon Kiat, Lim, Soon Thye, Chng, Wee Joo, Follows, George, Hodson, Daniel J., Du, Ming Qing, Goh, Yeow Tee, Tan, Suat Hoon, Grigoropoulos, Nicholas Francis, and Verma, Navin Kumar

Published
2021
Full Text
View/download PDF

18. CLL-106 First Prospective Data on Minimal Residual Disease Outcomes After Fixed-Duration Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for First-Line Treatment of CLL in Older Adult or Unfit Patients: The GLOW Study

Author

Munir, Talha, Moreno, Carol, Owen, Carolyn, Follows, George, Benjamini, Ohad, Janssens, Ann, Levin, Mark-David, Osterborg, Anders, Robak, Tadeusz, Simkovic, Martin, Stevens, Don, Voloshin, Sergey, Vorobyev, Vladimir, Yagci, Munci, Ysebaert, Loic, Qi, Qianya, Steele, Andrew, Schuier, Natasha, Baeten, Kurt, Caces, Donne Bennett, Niemann, Carsten, and Kater, Arnon

Published
2022
Full Text
View/download PDF

20. Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study

Author

Munir, Talha, primary, Moreno, Carol, additional, Owen, Carolyn, additional, Follows, George, additional, Benjamini, Ohad, additional, Janssens, Ann, additional, Levin, Mark-David, additional, Osterborg, Anders, additional, Robak, Tadeusz, additional, Simkovic, Martin, additional, Stevens, Don, additional, Voloshin, Sergey, additional, Vorobyev, Vladimir, additional, Yagci, Munci, additional, Ysebaert, Loic, additional, Qi, Keqin, additional, Qi, Qianya, additional, Parisi, Lori, additional, Srinivasan, Srimathi, additional, Schuier, Natasha, additional, Baeten, Kurt, additional, Howes, Angela, additional, Caces, Donne Bennett, additional, Niemann, Carsten U., additional, and Kater, Arnon P., additional

Published
2023
Full Text
View/download PDF

24. Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinemia: Patient outcomes and impact of bendamustine dosing

Author

Arulogun, Suzanne O., primary, Brian, Duncan, additional, Goradia, Harshita, additional, Cooney, Aaron, additional, Menne, Tobias, additional, Koo, RayMun, additional, O'Neill, Aideen T., additional, Vos, Josephine M. I., additional, Pratt, Guy, additional, Turner, Deborah, additional, Marshall, Kirsty, additional, Manos, Kate, additional, Anderson, Claire, additional, Gavriatopoulou, Maria, additional, Kyriakou, Charalampia, additional, Kersten, Marie J., additional, Minnema, Monique C., additional, Koutoumanou, Eirini, additional, El‐Sharkawi, Dima, additional, Linton, Kim, additional, Talaulikar, Dipti, additional, McCarthy, Helen, additional, Bishton, Mark, additional, Follows, George, additional, Wechalekar, Ashutosh, additional, and D'Sa, Shirley P., additional

Published
2023
Full Text
View/download PDF

25. Impact of Minimal Residual Disease on Progression-Free Survival Outcomes after Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study

Author

Munir, Talha, Moreno, Carol, Owen, Carolyn, Follows, George, Benjamini, Ohad, Janssens, Ann, Levin, Mark David, Osterborg, Anders, Robak, Tadeusz, Simkovic, Martin, Stevens, Don, Voloshin, Sergey, Vorobyev, Vladimir, Yagci, Munci, Ysebaert, Loic, Qi, Keqin, Qi, Qianya, Parisi, Lori, Srinivasan, Srimathi, Schuier, Natasha, Baeten, Kurt, Howes, Angela, Caces, Donne Bennett, Niemann, Carsten U., Kater, Arnon P., Munir, Talha, Moreno, Carol, Owen, Carolyn, Follows, George, Benjamini, Ohad, Janssens, Ann, Levin, Mark David, Osterborg, Anders, Robak, Tadeusz, Simkovic, Martin, Stevens, Don, Voloshin, Sergey, Vorobyev, Vladimir, Yagci, Munci, Ysebaert, Loic, Qi, Keqin, Qi, Qianya, Parisi, Lori, Srinivasan, Srimathi, Schuier, Natasha, Baeten, Kurt, Howes, Angela, Caces, Donne Bennett, Niemann, Carsten U., and Kater, Arnon P.

Abstract

PURPOSE In GLOW, fixed-duration ibrutinib + venetoclax showed superior progression-free survival (PFS) versus chlorambucil + obinutuzumab in older/comorbid patients with previously untreated chronic lymphocytic leukemia (CLL). The current analysis describes minimal residual disease (MRD) kinetics and any potential predictive value for PFS, as it has not yet been evaluated for ibrutinib + venetoclax treatment. METHODS Undetectable MRD (uMRD) was assessed by next-generation sequencing at <1 CLL cell per 10,000 (<10−4) and <1 CLL cell per 100,000 (<10−5) leukocytes. PFS was analyzed by MRD status at 3 months after treatment (EOT+3). RESULTS Ibrutinib + venetoclax achieved deeper uMRD (<10−5) rates in bone marrow (BM) and peripheral blood (PB), respectively, in 40.6% and 43.4% of patients at EOT+3 versus 7.6% and 18.1% of patients receiving chlorambucil + obinutuzumab. Of these patients, uMRD (<10−5) in PB was sustained during the first year post-treatment (EOT+12) in 80.4% of patients receiving ibrutinib + venetoclax and 26.3% receiving chlorambucil + obinutuzumab. Patients with detectable MRD (dMRD; ≥10−4) in PB at EOT+3 were more likely to sustain MRD levels through EOT+12 with ibrutinib + venetoclax versus chlorambucil + obinutuzumab. PFS rates at EOT+12 were high among patients treated with ibrutinib + venetoclax regardless of MRD status at EOT+3: 96.3% and 93.3% in patients with uMRD (<10−4) and dMRD (≥10−4) in BM, respectively, versus 83.3% and 58.7% for patients receiving chlorambucil + obinutuzumab. PFS rates at EOT+12 also remained high in patients with unmutated immunoglobulin heavy-chain variable region (IGHV) receiving ibrutinib + venetoclax, independent of MRD status in BM. CONCLUSION Molecular and clinical relapses were less frequent during the first year post-treatment with ibrutinib + venetoclax versus chlorambucil + obinutuzumab regardless of MRD status at EOT+3 and IGHV status. Even for p, PURPOSEIn GLOW, fixed-duration ibrutinib + venetoclax showed superior progression-free survival (PFS) versus chlorambucil + obinutuzumab in older/comorbid patients with previously untreated chronic lymphocytic leukemia (CLL). The current analysis describes minimal residual disease (MRD) kinetics and any potential predictive value for PFS, as it has not yet been evaluated for ibrutinib + venetoclax treatment.METHODSUndetectable MRD (uMRD) was assessed by next-generation sequencing at <1 CLL cell per 10,000 (<10-4) and <1 CLL cell per 100,000 (<10-5) leukocytes. PFS was analyzed by MRD status at 3 months after treatment (EOT+3).RESULTSIbrutinib + venetoclax achieved deeper uMRD (<10-5) rates in bone marrow (BM) and peripheral blood (PB), respectively, in 40.6% and 43.4% of patients at EOT+3 versus 7.6% and 18.1% of patients receiving chlorambucil + obinutuzumab. Of these patients, uMRD (<10-5) in PB was sustained during the first year post-treatment (EOT+12) in 80.4% of patients receiving ibrutinib + venetoclax and 26.3% receiving chlorambucil + obinutuzumab. Patients with detectable MRD (dMRD; ≥10-4) in PB at EOT+3 were more likely to sustain MRD levels through EOT+12 with ibrutinib + venetoclax versus chlorambucil + obinutuzumab. PFS rates at EOT+12 were high among patients treated with ibrutinib + venetoclax regardless of MRD status at EOT+3: 96.3% and 93.3% in patients with uMRD (<10-4) and dMRD (≥10-4) in BM, respectively, versus 83.3% and 58.7% for patients receiving chlorambucil + obinutuzumab. PFS rates at EOT+12 also remained high in patients with unmutated immunoglobulin heavy-chain variable region (IGHV) receiving ibrutinib + venetoclax, independent of MRD status in BM.CONCLUSIONMolecular and clinical relapses were less frequent during the first year post-treatment with ibrutinib + venetoclax versus chlorambucil + obinutuzumab regardless of MRD status at EOT+3 and IGHV status. Even for patients not achieving uMRD (<10-4), PFS rate

Published
2023

26. Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinemia: patient outcomes and impact of bendamustine dosing

Author

MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, Arulogun, Suzanne O, Brian, Duncan, Goradia, Harshita, Cooney, Aaron, Menne, Tobias, Koo, RayMun, O'Neill, Aideen T, Vos, Josephine M I, Pratt, Guy, Turner, Deborah, Marshall, Kirsty, Manos, Kate, Anderson, Claire, Gavriatopoulou, Maria, Kyriakou, Charalampia, Kersten, Marie J, Minnema, Monique C, Koutoumanou, Eirini, El-Sharkawi, Dima, Linton, Kim, Talaulikar, Dipti, McCarthy, Helen, Bishton, Mark, Follows, George, Wechalekar, Ashutosh, D'Sa, Shirley P, MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, Arulogun, Suzanne O, Brian, Duncan, Goradia, Harshita, Cooney, Aaron, Menne, Tobias, Koo, RayMun, O'Neill, Aideen T, Vos, Josephine M I, Pratt, Guy, Turner, Deborah, Marshall, Kirsty, Manos, Kate, Anderson, Claire, Gavriatopoulou, Maria, Kyriakou, Charalampia, Kersten, Marie J, Minnema, Monique C, Koutoumanou, Eirini, El-Sharkawi, Dima, Linton, Kim, Talaulikar, Dipti, McCarthy, Helen, Bishton, Mark, Follows, George, Wechalekar, Ashutosh, and D'Sa, Shirley P

Published
2023

28. BRAF inhibition in hairy cell leukemia with low-dose vemurafenib

Author

Dietrich, Sascha, Pircher, Andreas, Endris, Volker, Peyrade, Frédéric, Wendtner, Clemens-Martin, Follows, George A., Hüllein, Jennifer, Jethwa, Alexander, Ellert, Elena, Walther, Tatjana, Liu, Xiyang, Dyer, Martin J.S., Elter, Thomas, Brummer, Tilman, Zeiser, Robert, Hermann, Michael, Herold, Michael, Weichert, Wilko, Dearden, Claire, Haferlach, Torsten, Seiffert, Martina, Hallek, Michael, von Kalle, Christof, Ho, Anthony D., Gaehler, Anita, Andrulis, Mindaugas, Steurer, Michael, and Zenz, Thorsten

Published
2016
Full Text
View/download PDF

31. Relapsed mantle cell lymphoma presenting with lactic acidosis and hypoglycemia: A case report

Author

Carson, Lucy, Johnston, Andrew, Follows, George A, Santarsieri, Anna, Carson, Lucy [0000-0003-2770-3075], and Apollo - University of Cambridge Repository

Subjects
General Medicine
Abstract

Lactic acidosis and hypoglycemia are rare presentations of malignancy with a poor prognosis. We present the case of a mantle cell lymphoma patient who relapsed with lactic acidosis and hypoglycemia. Although blood glucose, pH, and lactate normalized following chemotherapy and intensive care support, the patient died from ventilator-associated pneumonia.

Published
2023

32. CLL-106 First Prospective Data on Minimal Residual Disease Outcomes After Fixed-Duration Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for First-Line Treatment of CLL in Older Adult or Unfit Patients:The GLOW Study

Author

Munir, Talha, Moreno, Carol, Owen, Carolyn, Follows, George, Benjamini, Ohad, Janssens, Ann, Levin, Mark-David, Osterborg, Anders, Robak, Tadeusz, Simkovic, Martin, Stevens, Don, Voloshin, Sergey, Vorobyev, Vladimir, Yagci, Munci, Ysebaert, Loic, Qi, Qianya, Steele, Andrew, Schuier, Natasha, Baeten, Kurt, Caces, Donne Bennett, Niemann, Carsten, Kater, Arnon, Hematology, AII - Cancer immunology, Experimental Immunology, Clinical Haematology, and CCA - Cancer Treatment and Quality of Life

Subjects
Cancer Research, MRD, Phase III, Oncology, venetoclax, ibrutinib, GLOW, minimal residual disease, chronic lymphocytic leukemia, Hematology, fixed-duration, CLL
Abstract

Context: Minimal residual disease (MRD) is a predictive marker for progression-free survival (PFS) in chronic leukocytic leukemia (CLL) following chemoimmunotherapy and fixed-duration treatment with venetoclax and anti-CD20 antibodies. This has not been explored for ibrutinib+venetoclax (Ibr+Ven), a fixed-duration treatment with mechanisms of action that synergistically eliminate CLL subpopulations in distinct tumor compartments. Objective: Investigate MRD outcomes at primary analysis of phase 3 GLOW study (NCT03462719). Design: Randomized, open-label, active-control study. Patients: Patients aged ≥65 years or 18–64 years with a CIRS score >6 or creatinine clearance –4); exploratory endpoints: MRD analyses. MRD results are by next-generation sequencing, reported 3 months after end of treatment (EOT+3) unless otherwise noted. Results: Rates of uMRD–4 were higher for Ibr+Ven versus Clb+O in bone marrow (BM) (51.9% vs. 17.1%; P–5 were higher for Ibr+Ven versus Clb+O in BM (40.6% vs. 7.6%), including patients with uIGHV (45.5% vs. 5.6%). uMRD–5 in PB was largely sustained from EOT+3 to EOT+12 with Ibr+Ven (80.4% [37/46]) but not Clb+O (26.3% [5/19]). PFS rates for Ibr+Ven during the 12 months after EOT were >90% for patients with uMRD–4 and patients with detectable MRD; however, Clb+O arm patients with detectable PB MRD relapsed more quickly than those with uMRD–4. Conclusions: All-oral, once-daily, fixed-duration Ibr+Ven demonstrated superior uMRD responses that were deeper and better sustained post-treatment versus Clb+O in older adult or unfit patients with previously untreated CLL.

Published
2022

33. R-DA-EPOCH Treatment Is Highly Effective Therapy for Primary Mediastinal Large B-Cell Lymphoma: A Real-World Multi-Centre Retrospective Evaluation

Author

Santarsieri, Anna, primary, Bennett, Rory, additional, Hopkins, David, additional, Lewis, Katharine L., additional, Gyansah, Cecilia N, additional, Cooke, Lisa, additional, Nagumantry, Sateesh K., additional, Shah, Nimish K., additional, Cheah, Chan Y., additional, McKay, Pamela, additional, Dickinson, Michael, additional, Seymour, John F., additional, and Follows, George A, additional

Published
2022
Full Text
View/download PDF

34. Replacing Procarbazine with Dacarbazine in Escalated Beacopp Dramatically Reduces the Post Treatment Haematopoietic Stem and Progenitor Cell Mutational Burden in Hodgkin Lymphoma Patients with No Apparent Loss of Clinical Efficacy

Author

Santarsieri, Anna, primary, Mitchell, Emily, additional, Sturgess, Katherine, additional, Brice, Pauline, additional, Menne, Tobias F., additional, Osborne, Wendy, additional, Creasey, Thomas, additional, Ardeshna, Kirit M., additional, Behan, Sarah, additional, Bhuller, Kaljit, additional, Booth, Stephen, additional, Chavda, Nikesh D., additional, Collins, Graham P., additional, Culligan, Dominic J., additional, Cwynarski, Kate, additional, Davies, Andrew, additional, Downing, Abigail, additional, Dutton, David, additional, Furtado, Michelle, additional, Gallop-Evans, Eve, additional, Hodson, Andrew, additional, Hopkins, David, additional, Hsu, Hannah, additional, Iyengar, Sunil, additional, Jones, Stephen G., additional, Linton, Kim M., additional, Lomas, Oliver C., additional, Martinez-Calle, Nicolas, additional, Mathur, Abhinav, additional, McKay, Pamela, additional, Nagumantry, Sateesh K., additional, O'Mahony, Deirdre, additional, Phillips, Elizabeth H., additional, Phillips, Neil, additional, Rudge, John F., additional, Shah, Nimish K., additional, Stafford, Gwyneth, additional, Sternberg, Alex, additional, Trickey, Rachel, additional, Uttenthal, Benjamin J., additional, Wetherall, Natasha, additional, McMillan, Andrew K., additional, Stratton, Michael, additional, Laurenti, Elisa, additional, Campbell, Peter J., additional, and Follows, George A., additional

Published
2022
Full Text
View/download PDF

35. Residual Disease Kinetics Among Patients with High-Risk Factors Treated with First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): The Glow Study

Author

Niemann, Carsten U, primary, Munir, Talha, additional, Moreno, Carol, additional, Owen, Carolyn, additional, Follows, George A, additional, Benjamini, Ohad, additional, Janssens, Ann, additional, Levin, Mark-David, additional, Österborg, Anders, additional, Robak, Tadeusz, additional, Šimkovič, Martin, additional, Voloshin, Sergey, additional, Vorobyev, Vladimir I., additional, Yagci, Munci, additional, Ysebaert, Loic, additional, Qi, Keqin, additional, Qi, Qianaya, additional, Parisi, Lori, additional, Srinivasan, Srimathi, additional, Schuier, Natasha, additional, Baeten, Kurt, additional, Howes, Angela, additional, Bennett Caces, Donne, additional, and Kater, Arnon P., additional

Published
2022
Full Text
View/download PDF

36. Oral Abstract: CLL-106 First Prospective Data on Minimal Residual Disease Outcomes After Fixed-Duration Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for First-Line Treatment of CLL in Older Adult or Unfit Patients: The GLOW Study

Author

Munir, Talha, primary, Moreno, Carol, additional, Owen, Carolyn, additional, Follows, George, additional, Benjamini, Ohad, additional, Janssens, Ann, additional, Levin, Mark-David, additional, Osterborg, Anders, additional, Robak, Tadeusz, additional, Simkovic, Martin, additional, Stevens, Don, additional, Voloshin, Sergey, additional, Vorobyev, Vladimir, additional, Yagci, Munci, additional, Ysebaert, Loic, additional, Qi, Qianya, additional, Steele, Andrew, additional, Schuier, Natasha, additional, Baeten, Kurt, additional, Caces, Donne Bennett, additional, Niemann, Carsten, additional, and Kater, Arnon, additional

Published
2022
Full Text
View/download PDF

37. Poster: CLL-106 First Prospective Data on Minimal Residual Disease Outcomes After Fixed-Duration Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for First-Line Treatment of CLL in Older Adult or Unfit Patients: The GLOW Study

Author

Munir, Talha, primary, Moreno, Carol, additional, Owen, Carolyn, additional, Follows, George, additional, Benjamini, Ohad, additional, Janssens, Ann, additional, Levin, Mark-David, additional, Osterborg, Anders, additional, Robak, Tadeusz, additional, Simkovic, Martin, additional, Stevens, Don, additional, Voloshin, Sergey, additional, Vorobyev, Vladimir, additional, Yagci, Munci, additional, Ysebaert, Loic, additional, Qi, Qianya, additional, Steele, Andrew, additional, Schuier, Natasha, additional, Baeten, Kurt, additional, Caces, Donne Bennett, additional, Niemann, Carsten, additional, and Kater, Arnon, additional

Published
2022
Full Text
View/download PDF

38. P015: Real World Escalated BEACOPDac Delivers Similar Outcomes to Escalated BEACOPP While Potentially Reducing Haematopoietic and Reproductive Toxicity

Author

Santarsieri, Anna, primary, Sturgess, Katherine, additional, Brice, Pauline, additional, Menne, Tobias F., additional, Osborne, Wendy, additional, Creasey, Thomas, additional, Ardeshna, Kirit M., additional, Behan, Sarah, additional, Bhuller, Kaljit, additional, Booth, Stephen, additional, Chavda, Nikesh, additional, Collins, Graham P., additional, Culligan, Dominic, additional, Cwynarski, Kate, additional, Davies, Andrew, additional, Dutton, David, additional, Furtado, Michelle, additional, Gallop-Evans, Eve, additional, Hodson, Andrew, additional, Hopkins, David, additional, Hsu, Hannah, additional, Iyengar, Sunil, additional, Jones, Stephen G., additional, Linton, Kim, additional, Lomas, Oliver, additional, Martinez-Calle, Nicolas, additional, Mathur, Abhinav, additional, Mckay, Pamela, additional, Nagumantry, Sateesh K., additional, O’Mahony, Deidre, additional, Phillips, Beth, additional, Phillips, Neil, additional, Rudge, John F., additional, Shah, Nimish, additional, Stafford, Gwyneth, additional, Sternberg, Alex, additional, Trickey, Rachel, additional, Uttenthal, Benjamin J., additional, Wetherall, Natasha, additional, Mcmillan, Andrew K., additional, and Follows, George A., additional

Published
2022
Full Text
View/download PDF

39. Managing relapsed refractory lymphoma with palliative oral chemotherapy: A multicentre retrospective study

Author

Bulley, Simon J., primary, Santarsieri, Anna, additional, Lentell, Isabel C., additional, O'Sullivan, Brendan, additional, Hodson, Andrew, additional, Firth, Oliver, additional, Sadullah, Shalal, additional, Follows, Annabel M., additional, Karanth, Mamatha, additional, Min, Sandra Young, additional, Fowler, Alexis, additional, Russell, James, additional, Uttenthal, Benjamin J., additional, Hodson, Daniel J., additional, and Follows, George A., additional

Published
2022
Full Text
View/download PDF

40. CLL-487 First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) vs Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-Up From the GLOW Study

Author

Moreno, Carol, Munir, Talha, Owen, Carolyn, Follows, George, Hernández-Rivas, José-Ángel, Benjamini, Ohad, Janssens, Ann, Levin, Mark-David, Robak, Tadeusz, Simkovic, Martin, Voloshin, Sergey, Vorobyev, Vladimir, Yagci, Munci, Ysebaert, Loic, Qi, Qianya, Smith, Emma, Srinivasan, Srimathi, Schuier, Natasha, Baeten, Kurt, Bennett Caces, Donne, Niemann, Carsten, and Kater, Arnon

Published
2024
Full Text
View/download PDF

41. First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) vs Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-Up From the GLOW Study

Author

Moreno, Carol, Munir, Talha, Owen, Carolyn, Follows, George, Hernández-Rivas, José-Ángel, Benjamini, Ohad, Janssens, Ann, Levin, Mark-David, Robak, Tadeusz, Simkovic, Martin, Voloshin, Sergey, Vorobyev, Vladimir, Yagci, Munci, Ysebaert, Loic, Qi, Qianya, Smith, Emma, Srinivasan, Srimathi, Schuier, Natasha, Baeten, Kurt, Bennett Caces, Donne, Niemann, Carsten, and Kater, Arnon

Published
2024
Full Text
View/download PDF

42. Introducing biomarkers for invasive fungal disease in haemato-oncology patients: a single-centre experience

Author

Martinelli, Anthony W., primary, Wright, Callum B., additional, Lopes, Marta S., additional, Swayne, Rosemary L., additional, Krishnamurthy, Pramila, additional, Crawley, Charles, additional, Uttenthal, Ben, additional, Follows, George, additional, Babar, Judith, additional, Aliyu, Sani H., additional, Enoch, David A., additional, and Sander, Clare R., additional

Published
2022
Full Text
View/download PDF

43. Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities

Author

Kater, Arnon P., primary, Owen, Carolyn, additional, Moreno, Carol, additional, Follows, George, additional, Munir, Talha, additional, Levin, Mark-David, additional, Benjamini, Ohad, additional, Janssens, Ann, additional, Osterborg, Anders, additional, Robak, Tadeusz, additional, Simkovic, Martin, additional, Stevens, Don, additional, Voloshin, Sergey, additional, Vorobyev, Vladimir, additional, Ysebaert, Loic, additional, Qin, Rui, additional, Steele, Andrew J., additional, Schuier, Natasha, additional, Baeten, Kurt, additional, Caces, Donne Bennett, additional, and Niemann, Carsten U., additional

Published
2022
Full Text
View/download PDF

45. Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Five-year follow-up of ELEVATE-TN.

Author

Sharman, Jeff Porter, primary, Egyed, Miklos, additional, Jurczak, Wojciech, additional, Skarbnik, Alan P., additional, Kamdar, Manali K., additional, Munir, Talha, additional, Fogliatto, Laura, additional, Herishanu, Yair, additional, Banerji, Versha, additional, Follows, George, additional, Walker, Patricia, additional, Karlsson, Karin, additional, Ghia, Paolo, additional, Janssens, Ann, additional, Ferrant, Emmanuelle, additional, Munugalavadla, Veerendra, additional, Yu, Ting, additional, Wang, Min Hui, additional, and Woyach, Jennifer Ann, additional

Published
2022
Full Text
View/download PDF

48. Incidence and outcomes of post-transplant lymphoproliferative disease after 5365 solid-organ transplants over a 20-year period at two UK transplant centres

Author

Santarsieri, Anna, Rudge, John F, Amin, Irum, Gelson, Will, Parmar, Jasvir, Pettit, Stephen, Sharkey, Lisa, Uttenthal, Benjamin J, Follows, George A, Santarsieri, Anna [0000-0002-4449-2196], and Apollo - University of Cambridge Repository

Subjects
Epstein-Barr Virus Infections, Incidence, Organ Transplantation, chemotherapy, Lymphoproliferative Disorders, United Kingdom, chop, surgical procedures, operative, hemic and lymphatic diseases, ebv, Humans, epidemiology, Rituximab, lymphoproliferative disease, Retrospective Studies
Abstract

Post-transplant lymphoproliferative disease (PTLD) is a life-threatening complication of solid-organ transplantation (SOT). We present the incidence and outcomes of PTLD in a cohort of 5365 SOT recipients over a 20-year period at two UK transplant centres. With a median follow-up of 7.7 years, 142 of 5365 patients have developed PTLD. Cumulative incidence was 18% at five years after multivisceral transplant and 1%-3% at five years following the other SOT types. Twenty-year cumulative incidence was 2%-3% following liver and heart transplantation and 10% following kidney transplantation. Median overall survival (OS) following SOT was 16 years, which is significantly reduced compared with the age-adjusted UK population. There is relatively high early mortality following diagnosis of PTLD and only patients surviving two years regained a longer-term survival approaching the non-PTLD SOT cohort. Of 90 patients with monomorphic PTLD, diffuse large B-cell lymphoma, 66 were treated with first-line rituximab monotherapy and 24 received first-line rituximab plus chemotherapy. Up-front rituximab monotherapy does not appear to compromise OS, but the number of patients dying from non-lymphoma causes before and after treatment remains high with both treatment approaches. Multivariate analysis of all 90 monomorphic PTLD patients identified an International Prognostic Index (IPI) of 3+ as the strongest pretreatment variable associating with inferior one-year OS.

Published
2022

49. Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes.

Author

UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Service de gastro-entérologie, UCL - (SLuc) Unité d'oncologie médicale, Casasnovas, Rene-Olivier, Follows, George, Zijlstra, Josee M, Vermaat, Joost S P, Kalakonda, Nagesh, Choquet, Sylvain, Neste, Eric Van Den, Hill, Brian, Thieblemont, Catherine, Cavallo, Federica, la Cruz, Fatima De, Kuruvilla, John, Hamad, Nada, Jaeger, Ulrich, Caimi, Paolo F, Gurion, Ronit, Warzocha, Krzysztof, Bakhshi, Sameer, Sancho, Juan-Manuel, Schuster, Michael, Egyed, Miklos, Offner, Fritz, Vassilakopoulos, Theodoros P, Samal, Priyanka, Ku, Matthew, Ma, Xiwen, Chamoun, Kamal, Shah, Jatin, Canales, Miguel, Maerevoet, Marie, Shacham, Sharon, Kauffman, Michael G, Goy, Andre, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Service de gastro-entérologie, UCL - (SLuc) Unité d'oncologie médicale, Casasnovas, Rene-Olivier, Follows, George, Zijlstra, Josee M, Vermaat, Joost S P, Kalakonda, Nagesh, Choquet, Sylvain, Neste, Eric Van Den, Hill, Brian, Thieblemont, Catherine, Cavallo, Federica, la Cruz, Fatima De, Kuruvilla, John, Hamad, Nada, Jaeger, Ulrich, Caimi, Paolo F, Gurion, Ronit, Warzocha, Krzysztof, Bakhshi, Sameer, Sancho, Juan-Manuel, Schuster, Michael, Egyed, Miklos, Offner, Fritz, Vassilakopoulos, Theodoros P, Samal, Priyanka, Ku, Matthew, Ma, Xiwen, Chamoun, Kamal, Shah, Jatin, Canales, Miguel, Maerevoet, Marie, Shacham, Sharon, Kauffman, Michael G, and Goy, Andre

Abstract

The SADAL study evaluated oral selinexor in patients with relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL) after at least 2 prior lines of systemic therapy. In this post-hoc analysis, we analyzed the outcomes of the SADAL study by DLBCL subtype to determine the effects of DLBCL subtypes on efficacy and tolerability of selinexor. Data from 134 patients in SADAL were analyzed by DLBCL subtypes for overall response rate (ORR), overall survival (OS), duration of treatment response, progression-free survival, and adverse events rate. ORR in the entire cohort was 29.1%, and similar in patients with germinal center (GCB) versus non-GCB DLBCL (31.7% vs. 24.2%, P = 0.45); transformed DLBCL showed a trend towards higher ORR than de novo DLBCL: 38.7% vs. 26.2% (P = 0.23). Despite similar prior treatment regimens and baseline characteristics, patients with DLBCL and normal C-MYC/BCL-2 protein expression levels had a significantly higher ORR (46.2% vs.14.8%, P = 0.012) and significantly longer OS (medians 13.7 vs. 5.1 months, hazard ratio 0.43 [95% CI, 0.23-0.77], P = 0.004) as compared with those whose DLBCL had C-MYC and BCL-2 overexpression. Among patients who had normal expression levels of either C-MYC or BCL-2 and baseline hemoglobin levels ≥ 10g/dL, ORR was 51.5% (n = 47), with median OS of 15.5 months and median PFS of 4.6 months. Similar rates of adverse events were noted in all subgroups. Overall, single agent oral selinexor showed strong responses in patients with limited treatment alternatives regardless of germinal center B-cell type or disease origin.

Published
2022

50. Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study.

Author

UCL - (SLuc) Centre du cancer, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - (SLuc) Service de rhumatologie, Schuster, Michael, Zijlstra, Josée, Casasnovas, Rene-Olivier, Vermaat, Joost S P, Kalakonda, Nagesh, Goy, Andre, Choquet, Sylvain, Neste, Eric Van Den, Hill, Brian, Thieblemont, Catherine, Cavallo, Federica, De la Cruz, Fatima, Kuruvilla, John, Hamad, Nada, Jaeger, Ulrich, Caimi, Paolo, Gurion, Ronit, Warzocha, Krzysztof, Bakhshi, Sameer, Sancho, Juan-Manuel, Follows, George, Egyed, Miklos, Offner, Fritz, Vassilakopoulos, Theodoros, Samal, Priyanka, Ku, Matthew, Ma, Xiwen, Corona, Kelly, Chamoun, Kamal, Shah, Jatin, Shacham, Sharon, Kauffman, Michael G, Canales, Miguel, Maerevoet, Marie, UCL - (SLuc) Centre du cancer, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - (SLuc) Service de rhumatologie, Schuster, Michael, Zijlstra, Josée, Casasnovas, Rene-Olivier, Vermaat, Joost S P, Kalakonda, Nagesh, Goy, Andre, Choquet, Sylvain, Neste, Eric Van Den, Hill, Brian, Thieblemont, Catherine, Cavallo, Federica, De la Cruz, Fatima, Kuruvilla, John, Hamad, Nada, Jaeger, Ulrich, Caimi, Paolo, Gurion, Ronit, Warzocha, Krzysztof, Bakhshi, Sameer, Sancho, Juan-Manuel, Follows, George, Egyed, Miklos, Offner, Fritz, Vassilakopoulos, Theodoros, Samal, Priyanka, Ku, Matthew, Ma, Xiwen, Corona, Kelly, Chamoun, Kamal, Shah, Jatin, Shacham, Sharon, Kauffman, Michael G, Canales, Miguel, and Maerevoet, Marie

Abstract

Despite a number of treatment options, patients with diffuse large B-cell lymphoma (DLBCL) whose disease has become refractory to treatment have a poor prognosis. Selinexor is a novel, oral drug that is approved to treat patients with relapsed/refractory DLBCL. In this post hoc analysis of the SADAL study, a multinational, open-label study, we evaluated subpopulations to determine if response to single agent selinexor is impacted by number of lines of prior treatment, autologous stem cell transplant (ASCT), response to first and most recent therapies, and time to progressive disease. Patients (n = 134) with DLBCL after 2-5 prior therapies were enrolled in SADAL and received 60mg selinexor twice weekly. The median overall survival was 9.0 months and median progression free survival was 2.6 months. Patients who had the best overall response rate (ORR) and disease control rate were those who had prior ASCT (42.5% and 50.0%) or responded to last line of therapy (35.9% and 43.5%). Patients with primary refractory DLBCL also showed responses (ORR 21.8%). Adverse events between subgroups were similar to the overall study population, the most common being thrombocytopenia (29.1%), fatigue (7.5%), and nausea (6.0%). Regardless of prior therapy and disease refractory status, selinexor treatment demonstrated results consistent with its novel mechanism of action and lack of cross-resistance. Thus, single agent oral selinexor can induce deep, durable, and tolerable responses in patients with DLBCL who have recurrent disease after several chemoimmunotherapy combination regimens.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results